Home
E-Submission
Sitemap
Contact Us
HOME
ABOUT
Aims and scope
About the journal
Editorial board
Principles of transparency and best practice
Management team
Open access
Subscription information
Contact us
BROWSE ARTICLES
All issues
Current issue
Ahead-of print articles
Most read articles
Most download articles
Most cited articles
Search
Author index
FOR AUTHORS AND REVIEWERS
Instructions for authors
Research and publication ethics
Author checklist
E-submission
Submission requirement form
Search
Search
Page Path
HOME
Search
Trimodality Therapy and Immuno-Oncology for Bladder Cancer
Original Article
Radical Cystectomy Versus Bladder-Preserving Therapy in Muscle-Invasive Bladder Cancer Patients After Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Retrospective Analysis
Youngheun Jo, Jun Seok Kim, Yoo Sub Shin, Jongchan Kim, Won Sik Jang, Jee Soo Park, Won Sik Ham
Journal of Urologic Oncology.
2023;21(2):165-173. Published online July 31, 2023
DOI:
https://doi.org/10.22465/juo.234600280014
Cited By 1
Full text
PubReader
ePub
PDF
Supplementary Material
1
Journal of
Urologic Oncology
Print ISSN: 2951-603X
Online ISSN: 2982-7043
MOST READ
MOST CITED
5,578
New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
5,030
The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
4,372
The Present and Future of Intravesical Therapy in Bladder Cancer
4,321
An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
4,296
Complex Epidemiology of Prostate Cancer in Asian Countries
+more
Cited By
7
Epidemiology of Urologic Cancer in Korea: Nationwide Trends in the Last 2 Decades
Cited By
4
An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer
Cited By
4
Complex Epidemiology of Prostate Cancer in Asian Countries
Cited By
3
The Evolving Role of Checkpoint Inhibitors in the Treatment of Urothelial Carcinoma: A Literature Review of Practice-Changing Trials
Cited By
2
Prostate Imaging and Reporting and Data System Version 2.1: Limitations for Clinical Use
+more